aidsmap: Modelling study backs targeted, not universal, lenacapavir PrEP for pregnancy and breastfeeding
A new modelling study suggests that targeted use of the drug lenacapavir for pregnant and breastfeeding women in high-incidence African districts is more cost-effective than universal rollout. Researchers emphasize that this should complement, not replace, existing vertical HIV transmission prevention programs.
Targeted deployment of twice-yearly lenacapavir for pregnant and breastfeeding women without HIV in high-incidence districts in sub-Saharan Africa could substantially reduce vertical transmission at a fraction of the cost of universal rollout, according to a modelling study published in the Journal of the International AIDS Society . But the authors say lenacapavir should be seen as complementary to, not a substitute for, strengthening existing programmes to prevent vertical transmission.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in